Projecting the Cost-effectiveness of Adherence Interventions in Persons with Human Immunodeficiency Virus Infection

American Journal of Medicine

Volumn 115, Issue 8, 2003, Pages 632-641

  Goldie, Sue J ^a,b   Paltiel, A David ^c   Weinstein, Milton C ^a   Losina, Elena ^d,e   Seage III, George R ^b   Kimmel, April D ^e   Walensky, Rochelle P ^e,f   Sax, Paul E ^f   Freedberg, Kenneth A ^a,d,e  

^a HARVARD CENTER FOR RISK ANALYSIS   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BOSTON UNIVERSITY   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; VIRUS RNA;

ACUTE DISEASE; ARTICLE; CELL COUNT; CHRONIC DISEASE; CLINICAL OBSERVATION; COHORT ANALYSIS; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; DEVICE; DISEASE COURSE; DISEASE SIMULATION; HEALTH CARE; HEALTH CARE COST; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFE EXPECTANCY; LIFESPAN; PATIENT COMPLIANCE; PREDICTION; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUALITY OF LIFE; STANDARD; URBAN POPULATION;

EID: 0345167938     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2003.07.007     Document Type: Article

References (59)

1. Palella F.J. Jr, Delaney K.M., Moorman A.C., et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 338:1998;853-860.
2. Ledergerber B., Egger M., Opravil M., et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet. 353:1999;863-868.
3. Gulick R.M., Mellors J.W., Havlir D., et al. 3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. Ann Intern Med. 133:2000;35-39.
4. Gross R., Bilker W.B., Friedman H.M., Strom B.L. Effect of adherence to newly initiated antiretroviral therapy on plasma viral load. AIDS. 15:2001;2109-2117.
5. Nieuwkerk P.T., Sprangers M.A., Burger D.M., et al. Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study. Arch Intern Med. 161:2001;1962-1968.
6. Lucas G.M., Chaisson R.E., Moore R.D. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med. 131:1999;81-87.
7. Garcia de Olalla P., Knobel H., Caroma A., et al. Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. J Acquir Immune Defic Syndr. 30:2002;105-110.
8. Descamps D., Flandre P., Calvez V., et al. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilege (Agence Nationale de Recherches sur le SIDA 072) Study Team [published correction appears in JAMA 2000;284-1518]. JAMA. 283:2000;205-211.
9. Paterson D.L., Swindells S., Mohr J., et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 133:2000;21-30.
10. McNabb J., Ross J.W., Abriola K., Turley C., Nightingale C.H., Nicolau D.P. Adherence to highly active antiretroviral therapy predicts virologic outcome at an inner-city human immunodeficiency virus clinic. Clin Infect Dis. 33:2001;700-705.
11. Roter D.L., Hall J.A., Merisca R., Nordstrom B., Cretin D., Svarstad B. Effectiveness of interventions to improve patient compliance: a meta-analysis. Med Care. 36:1998;1138-1161.
12. Ickovics J.R., Meisler A. Adherence in AIDS clinical trials: a framework for clinical research and clinical care. J Clin Epidemiol. 50:1997;385-391.
13. Liu H., Golin C.E., Miller L.G., et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med. 134:2001;968-977.
14. Bangsberg D.R., Perry S., Charlebois E.D., et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 15:2001;1181-1183.
15. Tuldra A., Fumaz C.R., Ferrer M.J., et al. Prospective randomized two-arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 25:2000;221-228.
16. Rigsby M.O., Rosen M.I., Beauvais J.E., et al. Cue-dose training with monetary reinforcement: pilot study of an antiretroviral adherence intervention. J Gen Intern Med. 15:2000;841-847.
17. Safren S.A., Otto M.W., Worth J.L., et al. Two strategies to increase adherence to HIV antiretroviral medication: life-steps and medication monitoring. Behav Res Ther. 39:2001;1151-1162.
18. Babudieri S., Aceti A., D'Offizi G.P., Carbonara S., Starnini G. Directly observed therapy to treat HIV infection in prisoners. JAMA. 284:2000;179-180.
19. Wu A.W. Adherence and health care utilization in HIV/AIDS-rational or rationalizing? J Gen Intern Med. 15:2000;891-893.
20. Gold M.R., Siegel J.E., Russell L.B., Weinstein M.C. Cost Effectiveness in Health and Medicine. 1996;Oxford University Press, New York, New York.
21. Freedberg K.A., Losina E., Weinstein M.C., et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med. 344:2001;824-831.
22. Paltiel A.D., Goldie S.J., Losina E., et al. Preevaluation of clinical trial data: the case of preemptive cytomegalovirus therapy in patients with human immunodeficiency virus. Clin Infect Dis. 32:2001;783-793.
23. Weinstein M.C., Goldie S.J., Losina E., et al. Use of genotypic resistance testing to guide HIV therapy clinical impact and cost-effectiveness . Ann Intern Med. 134:2001;440-450.
24. Mellors J.W., Munoz A., Giorgi J.V., et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 126:1997;946-954.
25. Release PO4. 1995;National Technical Information Service, Springfield, Virginia.
26. Staszewski S., Morales-Ramirez J., Tashima K.T., et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med. 341:1999;1865-1873.
27. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. Department of Health and Human Services and the Henry J. Kaiser Family Foundation. August 13, 2001. Available at: http://www.hivatis.org/ guidelines/adult/Aug13_01/text/testing.html. Accessed November 25, 2001.
28. 2001 USPHS/IDSA Guidelines for the Prevention of Opportunistic Infections in Persons Infected with Human Immunodeficiency Virus, Draft Guidelines July, 2001. Available at: http://www.hivatis.org/trtgdlns. html#Opportunistic. Accessed December 12, 2001.
29. Hammer S.M., Squires K.E., Hughes M.D., et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med. 337:1997;725-733.
30. El-Sadr W.M., Luskin-Hawk R., Yurik T.M., et al. A randomized trial of daily and thrice-weekly trimethoprim-sulfamethoxazole for the prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected persons. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). Clin Infect Dis. 29:1999;775-783.
31. Havlir D.V., Dube M.P., Sattler F.R., et al. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group. N Engl J Med. 335:1996;392-398.
32. Nightingale S.D., Cameron D.W., Gordin F.M., et al. Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. N Engl J Med. 329:1993;828-833.
33. Ioannidis J., Cappelleri J., Skolnik P., Lau J., Sacks H. A Meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens. Arch Intern Med. 156:1996;177-188.
34. El-Sadr W., Murphy R., Yurik T., et al. Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. N Engl J Med. 339:1998;1889-1895.
35. Public Use Tapes 4 and 5. 1994;National Technical Information Service, Springfield, Virginia.
36. Bozzette S.A., Joyce G., McCaffrey D.F., et al. Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. N Engl J Med. 344:2001;817-823.
37. Holtgrave D.R., Pinkerton S.D. Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs. J Acquir Immune Defic Syndr Hum Retrovirol. 16:1997;54-62.
38. Drug Topics Red Book. Montvale, New Jersey: Medical Economics; 2001.
39. 2001 Clinical Diagnostic Laboratory Fee Schedule. Public Use File (PUF). Baltimore, Maryland: Health Care Financing Administration; 2001. Available at: http://www.hcfa.gov/stats/pufiles.htm#labfee. Accessed March 2, 2002.
40. Moore R.D., Chaulk C.P., Griffiths R., Cavalcante S., Chaisson R.E. Cost-effectiveness of directly observed versus self-administered therapy for tuberculosis. Am J Respir Crit Care Med. 154:1996;1013-1019.
41. Burman W.J., Dalton C.B., Cohn D.L., Butler J.R., Reves R.R. A cost-effectiveness analysis of directly observed therapy vs self-administered therapy for treatment of tuberculosis. Chest. 112:1997;63-70.
42. Palmer C., Miller B., Halpern M., Geiter L. A model of the cost-effectiveness of directly observed therapy for treatment of tuberculosis. J Public Health Manage Pract. 4:1998;1-13.
43. U.S. Bureau of Labor Statistics. Statistical Abstract of the United States. USDL 96-186. Washington, DC: U.S. Government Printing Office; 2001. Accessed February 13, 2003.
44. Baxter J.D., Mayers D.L., Wentworth D.N., et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS. 14:2000;F83-F93.
45. Gulick R.M., Mellors J.W., Havlir D., et al. Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamuvidine for HIV-1 infection, 100 week follow-up. JAMA. 280:1998;35-41.
46. Montaner J.S., Reiss P., Cooper D., et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients the INCAS Trial. Italy, The Netherlands, Canada and Australia Study . JAMA. 279:1998;930-937.
47. Dougherty G., Schiffrin A., White D., Soderstrom L., Sufrategui M. Home-based management can achieve intensification cost-effectively in type I diabetes. Pediatrics. 103:1999;122-128.
48. Keeler E.B., Robalino D.A., Frank J.C., Hirsch S.H., Maly R.C., Reuben D.B. Cost-effectiveness of outpatient geriatric assessment with an intervention to increase adherence. Med Care. 37:1999;1199-1206.
49. Andrade A. HIV adherence strategies take a high-tech route. AIDS Alert. 16:2001;97-98.
50. e-pill Medication Reminders. Available at: http://www.epill.com/bysku. html . Accessed May 8, 2003.
51. Energizer E91BP-8 AA Batteries (8-Pack) $8.99. Available at http://www.amazon.com/exec/obidos/tg/detail/. Accessed May 8, 2003.
52. Statistical Abstract of the United States: Consumer Price Index - All Urban Consumers. Washington, D.C.: National Center for Health Statistics; 2001. Available: http://www.cdc.gov/nchswwn/daa/gm291_1.pdf. Accessed May 8, 2003.
53. Anderson R.N. United States life tables. U.S. Decennial Life Tables for 1989-91. 1999;National Center for Health Statistics, Hyattsville, Maryland.
54. Schackman B.R., Goldie S.J., Freedberg K.A., Losina E., Brazier J., Weinstein M.C. Comparison of health state utilities using community and patient preference weights derived from a survey of patients with HIV/AIDS. Med Decis Making. 22:2002;27-38.
55. Brazier J., Usherwood T., Harper R., Thomas K. Deriving a preference-based single index from the UK SF-36 Health Survey. J Clin Epidemiol. 51:1998;1115-1128.
56. Bozzette S.A., Berry S.H., Duan N., et al. The care of HIV-infected adults in the United States. HIV Cost and Services Utilization Study Consortium. N Engl J Med. 339:1998;1897-1904.
57. Levitz S.M. Improvement in CD4+ cell counts despite persistently detectable HIV load. N Engl J Med. 338:1998;1074-1075.
58. Tchetgen E., Kaplan E.H., Friedland G.H. Public health consequences of screening patients for adherence to highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 26:2001;118-129.
59. Markowitz M. Resistance, fitness, adherence, and potency mapping the paths to virologic failure . JAMA. 283:2000;250-251.